Date published: 2025-10-27

1-800-457-3801

SCBT Portrait Logo
Seach Input

β-defensin 38 Inhibitors

β-defensin 38 inhibitors are a class of compounds that interact specifically with β-defensin 38, a member of the defensin family of small, cysteine-rich cationic proteins. β-defensins are predominantly known for their role in innate immunity, acting as antimicrobial peptides that help protect against bacterial, fungal, and viral pathogens. However, beyond their antimicrobial activity, β-defensins, including β-defensin 38, are implicated in a variety of biological processes, such as modulating inflammation, signaling pathways, and influencing cellular functions. Inhibitors of β-defensin 38 can interfere with these non-microbial activities, potentially modulating its interactions with other molecular components in the cellular environment. The specificity and efficacy of β-defensin 38 inhibitors are dependent on their ability to bind to the peptide with high affinity, preventing it from exerting its natural functions. These interactions are complex, often involving key structural motifs or domains within the β-defensin molecule, such as the cysteine-stabilized α/β motifs, which are critical for its bioactivity.

Chemically, β-defensin 38 inhibitors can vary widely in structure, from small molecules to peptides, each with distinct mechanisms of action. Some inhibitors may work by directly binding to the active site of β-defensin 38, thereby preventing it from interacting with its target receptors or substrates, while others might function by altering the folding or stability of the peptide, thus impeding its function. Structural studies, such as X-ray crystallography or NMR spectroscopy, are often employed to elucidate the binding interactions and to design more effective inhibitors. Moreover, computational modeling and molecular dynamics simulations have become crucial tools for understanding the binding affinities and conformational changes that occur upon inhibitor binding. These studies help to map the interaction surfaces and identify key residues that are critical for binding, which is invaluable for the design and optimization of novel inhibitors. Understanding the chemical characteristics and binding dynamics of β-defensin 38 inhibitors is essential for elucidating their roles in modulating the diverse biological activities of β-defensin 38, ultimately contributing to a broader understanding of the regulatory mechanisms of β-defensins in physiological contexts.

SEE ALSO...

Items 1 to 10 of 11 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Olaparib

763113-22-0sc-302017
sc-302017A
sc-302017B
250 mg
500 mg
1 g
$206.00
$299.00
$485.00
10
(1)

PARP inhibitor disrupting DNA repair. Olaparib indirectly inhibits β-defensin 38 by interfering with the DNA damage response pathway, impacting the regulation of β-defensin 38 transcription under conditions of cellular stress.

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$121.00
$392.00
148
(1)

PI3K inhibitor disrupting the PI3K/AKT pathway. LY294002 indirectly hampers β-defensin 38, as PI3K/AKT signaling is implicated in the regulation of β-defensin 38 transcription by modulating specific transcription factors.

Cyclosporin A

59865-13-3sc-3503
sc-3503-CW
sc-3503A
sc-3503B
sc-3503C
sc-3503D
100 mg
100 mg
500 mg
10 g
25 g
100 g
$62.00
$90.00
$299.00
$475.00
$1015.00
$2099.00
69
(5)

Calcineurin inhibitor affecting the NFAT pathway. Cyclosporin A indirectly inhibits β-defensin 38 by blocking NFAT activation, a key regulator of β-defensin 38 transcription in response to various stimuli.

Trametinib

871700-17-3sc-364639
sc-364639A
sc-364639B
5 mg
10 mg
1 g
$112.00
$163.00
$928.00
19
(1)

MEK inhibitor influencing the MAPK/ERK pathway. Trametinib indirectly influences β-defensin 38 expression by disrupting the MAPK/ERK pathway, which modulates β-defensin 38 transcription through specific downstream effectors.

SP600125

129-56-6sc-200635
sc-200635A
10 mg
50 mg
$40.00
$150.00
257
(3)

JNK inhibitor affecting the AP-1 pathway. SP600125 indirectly hinders β-defensin 38, as the AP-1 transcription factor, downstream of JNK, is involved in the transcriptional regulation of β-defensin 38.

Suberoylanilide Hydroxamic Acid

149647-78-9sc-220139
sc-220139A
100 mg
500 mg
$130.00
$270.00
37
(2)

HDAC inhibitor modulating chromatin structure. Vorinostat indirectly suppresses β-defensin 38 by altering histone acetylation, influencing the accessibility of the β-defensin 38 gene for transcription.

XAV939

284028-89-3sc-296704
sc-296704A
sc-296704B
1 mg
5 mg
50 mg
$35.00
$115.00
$515.00
26
(1)

Wnt/β-catenin pathway inhibitor. XAV939 indirectly inhibits β-defensin 38, as the Wnt/β-catenin pathway is implicated in regulating β-defensin 38 expression by modulating the activity of specific transcription factors.

Deferoxamine mesylate

138-14-7sc-203331
sc-203331A
sc-203331B
sc-203331C
sc-203331D
1 g
5 g
10 g
50 g
100 g
$255.00
$1039.00
$2866.00
$4306.00
$8170.00
19
(1)

HIF-1α inhibitor affecting the hypoxia pathway. Deferoxamine indirectly suppresses β-defensin 38, as HIF-1α enhances β-defensin 38 transcription under hypoxic conditions, and inhibiting HIF-1α disrupts this regulatory mechanism.

Eprosartan

133040-01-4sc-207631
10 mg
$166.00
1
(0)

TLR4 inhibitor affecting the TLR4 signaling pathway. CLI-095 indirectly hampers β-defensin 38, as TLR4 activation is known to upregulate β-defensin 38 expression through NF-κB and AP-1 signaling cascades.

Rapamycin

53123-88-9sc-3504
sc-3504A
sc-3504B
1 mg
5 mg
25 mg
$62.00
$155.00
$320.00
233
(4)

mTOR inhibitor influencing the mTORC1 pathway. Rapamycin indirectly inhibits β-defensin 38 by modulating mTORC1 signaling, which is implicated in the regulation of β-defensin 38 through control of translation initiation.